XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Disaggregated Revenues
 3 Months Ended
Mar. 31, 2024
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):
Three Months Ended
March 31,
20242023
(unaudited)
Net product sales
Qelbree$45,104 $25,782 
Oxtellar XR26,943 28,915 
GOCOVRI26,562 26,010 
APOKYN16,649 17,209 
Trokendi XR15,989 34,790 
Other(1)
7,214 7,869 
Total net product sales$138,461 $140,575 
Royalty and licensing revenues5,183 13,189 
Total revenues$143,644 $153,764 
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
The Company recognized noncash royalty revenue of $2.3 million for the three months ended March 31, 2023. The Company no longer recognizes noncash royalty revenue as ownership of the royalty rights reverted back to the Company during the second quarter of 2023.
The following table shows the percentage of net product sales to total net product sales:

Percentage of Net Product Sales
Three Months Ended March 31,
20242023
(unaudited)
Qelbree33%18%
Oxtellar XR19%21%
GOCOVRI19%18%
APOKYN12%12%
Trokendi XR12%25%
Other(1)
5%6%
Total100%100%
___________________________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Each of our three major customers, Cencora, Inc., Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total gross product sales and collectively accounted for more than 70% of our total gross product sales for the three months ended March 31, 2024 and 2023.